Becton Dickinson and Co (BDX) Position Lowered by Sustainable Growth Advisers LP
Sustainable Growth Advisers LP decreased its holdings in Becton Dickinson and Co (NYSE:BDX) by 2.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 719,473 shares of the medical instruments supplier’s stock after selling 15,638 shares during the quarter. Becton Dickinson and makes up 2.1% of Sustainable Growth Advisers LP’s portfolio, making the stock its 23rd biggest position. Sustainable Growth Advisers LP owned 0.27% of Becton Dickinson and worth $187,782,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the stock. Acropolis Investment Management LLC acquired a new stake in Becton Dickinson and during the third quarter valued at approximately $101,000. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and during the second quarter valued at approximately $105,000. Truvestments Capital LLC acquired a new stake in Becton Dickinson and during the third quarter valued at approximately $105,000. Bartlett & Co. LLC raised its stake in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 435 shares in the last quarter. Finally, Bridgeworth LLC acquired a new stake in Becton Dickinson and during the second quarter valued at approximately $131,000. Institutional investors and hedge funds own 92.70% of the company’s stock.
In other news, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP James C. Lim sold 5,189 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the sale, the executive vice president now owns 13,318 shares in the company, valued at $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.
Shares of Becton Dickinson and stock opened at $236.22 on Tuesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. The company has a market cap of $65.09 billion, a PE ratio of 21.46, a P/E/G ratio of 1.67 and a beta of 1.19. Becton Dickinson and Co has a twelve month low of $209.91 and a twelve month high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.93. The business had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The business’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.40 EPS. As a group, research analysts expect that Becton Dickinson and Co will post 12.2 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Position Lowered by Sustainable Growth Advisers LP” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/11/13/becton-dickinson-and-co-bdx-position-lowered-by-sustainable-growth-advisers-lp.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Read More: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.